Semaglutide: The Drug That Put GLP-1s on the Map

Semaglutide is the drug that made everyone know what a GLP-1 is. Before Ozempic became a household word, this class of medicine lived quietly in diabetes clinics. Now your aunt knows what a GLP-1 is. The SELECT cardiovascular trial. The STEP trials for weight loss. The spike in demand, the shortages, the compounded-vs-branded debate — semaglutide set the template for everything that came after it.

It's not the strongest GLP-1 anymore. Tirzepatide wins head-to-head. But semaglutide is still the reference drug, and for a lot of people it's still the right choice.

What it is, in one paragraph

Semaglutide is a modified GLP-1 analog with an alpha-aminoisobutyric acid swap (blocks DPP-4), a fatty-acid chain at Lys26 (binds albumin, extends half-life to ~7 days), and some other tweaks for stability. It hits the GLP-1 receptor in the pancreas (insulin secretion, glucagon suppression), the hypothalamus (appetite), the stomach (delayed gastric emptying), and basically every other tissue that expresses GLP-1R — which is more than people realize. Once-weekly sub-Q (Ozempic, Wegovy) or once-daily oral (Rybelsus).

Dosing: what people actually do

The Wegovy titration is the template for weight management:

• Weeks 1–4: 0.25 mg weekly
• Weeks 5–8: 0.5 mg weekly
• Weeks 9–12: 1.0 mg weekly
• Weeks 13–16: 1.7 mg weekly
• Week 17+: 2.4 mg weekly (maintenance)

The Ozempic T2D titration tops out at 1.0 or 2.0 mg. Forum users run a huge range:

• Low-and-slow: 0.25–0.5 mg indefinitely, mild appetite effect, minimal GI
• Standard weight loss: 1.0–1.7 mg, the sweet spot for most
• Aggressive: 2.4 mg if weight loss stalls
• Microdosing: 0.1–0.25 mg weekly, especially for maintenance after a course, is a surprisingly common late-game strategy

"Ran 1.0 mg for six months, lost 38 lb. Dropped to 0.25 mg for maintenance. Been there a year and a half. The drug at 0.25 is barely noticeable — but it's enough that I'm not hungry all day like I was before." — forum user

What it pairs with

• Resistance training + high protein — as with every drug in this class, lean mass defense is the job
• Creatine, electrolytes — basics get you 80% of the way through side-effect management
• 5-Amino-1MQ — the metabolic add-on the forums keep coming back to
• BPC-157 — for managing GI during titration (anecdotal, widespread)
• Not usually stacked with tirz or reta. Pick an incretin

Red flags and side effects

• GI: the classic list — nausea, vomiting, diarrhea, constipation. Worst during dose escalation
• Gallbladder issues — rapid weight loss raises stone risk
• Gastroparesis — rare, serious. Persistent severe nausea is a flag
• Lean mass loss — ~25–40% of weight lost if you don't actively defend
• Rebound — stopping cold means regaining ~2/3 within a year (STEP-1 extension)
• Mood/reward effects — some users report reduced cravings beyond food (alcohol, shopping). Mechanism is real but poorly characterized
• Injection-site reactions — uncommon, mostly transient

The honest limits

• Tirzepatide outperforms it head-to-head for both glycemic control and weight loss
• It's a long-term drug for most people. The regain is aggressive without maintenance
• Compounded semaglutide quality is all over the place. Branded is expensive; compounded is a gamble unless you have a COA
• The cardiovascular benefit (SELECT trial) is real and meaningful — this is a differentiator from tirz, which doesn't have the same depth of CV data yet
• Non-metabolic uses (alcohol, addiction, Alzheimer's) are promising in signal but not yet in conclusion

Where to go next

• For the full mechanism, trial portfolio, and comparison to other GLP-1s, see the Pepperpedia Semaglutide entry.
• For dosing logs, compounded-vs-branded threads, and microdosing maintenance protocols, the Optimization forum is the community hub.
• Need to convert a 10 mg vial into weekly units? PepperCalc handles it.
• Comparing to the rest of the class? See Tirzepatide and Retatrutide.